TRAIL is a promising anticancer active molecule because of its ability to selectively bind to proapoptotic death receptors, which are frequently overexpressed in a wide range of tumor cells, subsequently inducing apoptosis in these cells.[104] However, the use of TRAIL is limited due to instability, easy removal, and requiring repeated dosing to maintain the effective concentration of TRAIL in cancer. The gene discussed is TNFSF10; the disease is neoplasm.